Drug Profile
Lunacalcipol
Alternative Names: CTA-018; CTA018 Capsule; CTA018 Cream; CTA018 Injection; Lunacalcipol; MT-2832Latest Information Update: 07 Feb 2017
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Cytochroma; OPKO Health
- Class Antipsoriatics; Vitamin D analogues
- Mechanism of Action Calcitriol stimulants; CYP24 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis; Secondary hyperparathyroidism
Most Recent Events
- 07 Feb 2017 Discontinued - Phase-II for Secondary hyperparathyroidism in USA (IV)
- 23 May 2016 OPKO Health plans a phase IIb trial for Secondary hyperparathyroidism in USA (IV) (OPKO Health website, May 2016)
- 24 Apr 2014 Phase-II clinical trials in Secondary hyperparathyroidism in USA (IV)